SG Americas Securities
RCKT icon

SG Americas Securities’s Rocket Pharmaceuticals RCKT Stock Holding History

SG Americas Securities’s Portfolio RCKT Stock Details RCKT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$64K Sell
18,819
-314
-2% -$1.04K ﹤0.01% 3183
2026
Q1 		$68K Sell
19,133
-44,615
-70% -$177K ﹤0.01% 2995
2025
Q4 		$224K Buy
63,748
+15,019
+31% +$51.4K ﹤0.01% 2884
2025
Q3 		$159K Sell
48,729
-14,824
-23% -$46.7K ﹤0.01% 2873
2025
Q2 		$156K Sell
63,553
-53,018
-45% -$269K ﹤0.01% 2416
2025
Q1 		$778K Buy
116,571
+61,650
+112% +$609K ﹤0.01% 1397
2024
Q4 		$690K Buy
54,921
+48,793
+796% +$734K ﹤0.01% 1085
2024
Q3 		$113K Buy
+6,128
New +$126K ﹤0.01% 2968
2024
Q2 		– Sell
-8,765
Closed -$236K – 3234
2024
Q1 		$236K Sell
8,765
-9,607
-52% -$273K ﹤0.01% 1860
2023
Q4 		$551K Sell
18,372
-63,575
-78% -$1.4M 0.01% 1416
2023
Q3 		$1.68M Buy
+81,947
New +$1.49M 0.02% 869
2023
Q2 		– Sell
-11,612
Closed -$199K – 3001
2023
Q1 		$199K Buy
11,612
+1,340
+13% +$26.2K ﹤0.01% 2419
2022
Q4 		$201K Sell
10,272
-22,094
-68% -$407K ﹤0.01% 2189
2022
Q3 		$517K Sell
32,366
-16,876
-34% -$263K 0.01% 1522
2022
Q2 		$678K Buy
+49,242
New +$587K 0.01% 1680
2022
Q1 		– Sell
-79,622
Closed -$1.74M – 3344
2021
Q4 		$1.74M Buy
79,622
+58,775
+282% +$1.6M 0.01% 1197
2021
Q3 		$623K Buy
20,847
+17,091
+455% +$622K ﹤0.01% 2319
2021
Q2 		$166K Sell
3,756
-5,777
-61% -$251K ﹤0.01% 2423
2021
Q1 		$423K Buy
9,533
+2,719
+40% +$149K ﹤0.01% 2129
2020
Q4 		$374K Sell
6,814
-1,887
-22% -$68.8K ﹤0.01% 2208
2020
Q3 		$199K Buy
8,701
+131
+2% +$3.23K ﹤0.01% 2159
2020
Q2 		$179K Buy
+8,570
New +$155K ﹤0.01% 2949
2017
Q2 		– Sell
-3,446
Closed -$28K – 3443
2017
Q1 		$28K Buy
3,446
+736
+27% +$4.95K ﹤0.01% 3166
2016
Q4 		$66K Buy
+2,710
New +$77.3K ﹤0.01% 2912
2016
Q2 		– Sell
-2,905
Closed -$86K – 2915
2016
Q1 		$86K Buy
+2,905
New +$87.2K ﹤0.01% 2665

Other funds holding RCKT

RI
RTW Investments New York $11.7B AUM 174.13% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Citigroup
Citigroup New York $303B AUM 53.02% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return
Millennium Management
Millennium Management New York $276B AUM 44.8% 1-Year Est. Return
NM
Newtyn Management New York $801M AUM 23.14% 1-Year Est. Return
MC
Maverick Capital Dallas, Texas $11.3B AUM 76.6% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
AQR Capital Management
AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

SG Americas Securities's RCKT Position: Q2 2026 in Review

SG Americas Securities reduced its Rocket Pharmaceuticals (RCKT) stake by 1.6% in Q2 2026, selling an estimated $1.04K and leaving 18,819 shares worth $64K. The position accounts for ﹤0.01% of the portfolio, ranked #3183.

SG Americas Securities first reported a position in RCKT in Q1 2016 and has held it in 25 quarters since. The position peaked at $1.74M in Q4 2021. 180 funds tracked by Wall St. Rank hold RCKT as of Q2 2026.

  • SG Americas Securities held 18,819 shares of Rocket Pharmaceuticals worth $64K as of Q2 2026.
  • SG Americas Securities sold 314 Rocket Pharmaceuticals shares in Q2 2026, an estimated $1.04K.
  • Rocket Pharmaceuticals made up ﹤0.01% of SG Americas Securities's portfolio in Q2 2026, its #3183 holding.
  • SG Americas Securities first reported a position in Rocket Pharmaceuticals in Q1 2016 and has held it in 25 quarters since.
  • SG Americas Securities's Rocket Pharmaceuticals position peaked at $1.74M in Q4 2021.
  • 180 funds tracked by Wall St. Rank held Rocket Pharmaceuticals as of Q2 2026.

Based on SG Americas Securities's 13F filing for Q2 2026, filed 7 Aug 2026.